CBD Reduced Gut Symptoms of Opioid Withdrawal in Mice

CBD dose-dependently reduced gastrointestinal symptoms of opioid withdrawal in both male and female mice, suggesting a potential therapeutic target for managing withdrawal discomfort.

Scicluna, Rhianne L et al.·Cannabis and cannabinoid research·2024·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-05692Animal StudyPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

CBD at 10, 30, and 100 mg/kg dose-dependently reduced gastrointestinal symptoms (diarrhea, fecal output, weight loss) during both precipitated and spontaneous oxycodone withdrawal in male mice and during precipitated withdrawal in female mice. Effects on other withdrawal symptoms (jumping, paw tremors) were less consistent.

Key Numbers

CBD tested at 10, 30, and 100 mg/kg. Oxycodone escalated from 9 to 33 mg/kg over 8 days. Male mice showed withdrawal effects in both precipitated and spontaneous conditions; female mice only showed precipitated withdrawal effects. GI symptom reduction was consistent across both sexes in precipitated withdrawal.

How They Did This

Mice received escalating oxycodone doses over 8 days, then underwent either naloxone-precipitated or spontaneous withdrawal. CBD was administered 60 minutes before testing at 0, 10, 30, or 100 mg/kg. Gastrointestinal symptoms, somatic symptoms, and negative affect behaviors were measured.

Why This Research Matters

Opioid withdrawal is a major driver of continued drug use, and current treatments have limitations. The gastrointestinal symptoms (nausea, diarrhea, cramping) are among the most distressing. Finding that CBD specifically targets these symptoms opens a potential complementary treatment avenue.

The Bigger Picture

The opioid crisis has driven interest in non-opioid approaches to managing withdrawal. CBD, which is already available clinically and has a favorable safety profile, could potentially be integrated into withdrawal management protocols if these findings translate to humans.

What This Study Doesn't Tell Us

Animal study results may not translate to humans. Doses used were relatively high. Female mice showed less robust withdrawal syndrome overall, making it harder to evaluate CBD's effects in that group. The study did not examine long-term outcomes or relapse.

Questions This Raises

  • ?Why did female mice show a less pronounced withdrawal syndrome?
  • ?Would CBD be effective at clinically relevant doses in humans?
  • ?Could CBD be combined with existing withdrawal medications for additive benefit?

Trust & Context

Key Stat:
CBD reduced GI withdrawal symptoms at all three doses tested
Evidence Grade:
Well-designed animal study with dose-response data and sex comparisons, but preclinical findings require human validation.
Study Age:
2024 study (published 2022 online, journal 2024)
Original Title:
Cannabidiol Reduced the Severity of Gastrointestinal Symptoms of Opioid Withdrawal in Male and Female Mice.
Published In:
Cannabis and cannabinoid research, 9(2), 547-560 (2024)
Database ID:
RTHC-05692

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can CBD help with opioid withdrawal?

In mice, CBD reduced the gastrointestinal symptoms of opioid withdrawal (diarrhea, weight loss) in a dose-dependent manner. Human studies are still needed.

Which opioid withdrawal symptoms did CBD affect?

CBD was most effective against gastrointestinal symptoms. It had less consistent effects on other withdrawal behaviors like jumping and paw tremors.

Read More on RethinkTHC

Cite This Study

RTHC-05692·https://rethinkthc.com/research/RTHC-05692

APA

Scicluna, Rhianne L; Wilson, Bianca B; Thelaus, Samuel H; Arnold, Jonathon C; McGregor, Iain S; Bowen, Michael T. (2024). Cannabidiol Reduced the Severity of Gastrointestinal Symptoms of Opioid Withdrawal in Male and Female Mice.. Cannabis and cannabinoid research, 9(2), 547-560. https://doi.org/10.1089/can.2022.0036

MLA

Scicluna, Rhianne L, et al. "Cannabidiol Reduced the Severity of Gastrointestinal Symptoms of Opioid Withdrawal in Male and Female Mice.." Cannabis and cannabinoid research, 2024. https://doi.org/10.1089/can.2022.0036

RethinkTHC

RethinkTHC Research Database. "Cannabidiol Reduced the Severity of Gastrointestinal Symptom..." RTHC-05692. Retrieved from https://rethinkthc.com/research/scicluna-2024-cannabidiol-reduced-the-severity

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.